Cargando…
Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer
OBJECTIVE: To evaluate the outcome following the strategy of endoscopic R0 resection (ER) plus adjuvant treatment (AT) versus esophagectomy for esophageal squamous cell cancer in T1a invading muscularis mucosa (M3)-T1b stage. METHODS: We evaluated the outcomes of 46 esophageal squamous cell cancer (...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979881/ https://www.ncbi.nlm.nih.gov/pubmed/33893544 http://dx.doi.org/10.1007/s00464-021-08466-2 |
_version_ | 1784681274728775680 |
---|---|
author | Huang, Binhao Xu, Maria Christine Pennathur, Arjun Li, Zhigang Liu, Zhiguo Wu, Qi Wang, Jing Luo, Kongjia Bai, Jianying Wei, Zhi Xiang, Jiaqing Fang, Wentao Zhang, Jie |
author_facet | Huang, Binhao Xu, Maria Christine Pennathur, Arjun Li, Zhigang Liu, Zhiguo Wu, Qi Wang, Jing Luo, Kongjia Bai, Jianying Wei, Zhi Xiang, Jiaqing Fang, Wentao Zhang, Jie |
author_sort | Huang, Binhao |
collection | PubMed |
description | OBJECTIVE: To evaluate the outcome following the strategy of endoscopic R0 resection (ER) plus adjuvant treatment (AT) versus esophagectomy for esophageal squamous cell cancer in T1a invading muscularis mucosa (M3)-T1b stage. METHODS: We evaluated the outcomes of 46 esophageal squamous cell cancer (ESCC) patients with T1aM3-T1b stage who underwent ER + AT from the Esophageal Cancer Endoscopic Therapy Consortium (ECETC) and compared these outcomes to 92 patients who underwent esophagectomy. Propensity score matching (1:2) was used, with overall survival (OS) and relapse-free survival (RFS) being compared between the two groups. RESULTS: During a median follow-up of 32 months, there were no statistical differences (P = 0.226) in OS between the two groups. The 1-, 2-, and 3-year overall survival in the esophagectomy group was 95%, 91%, and 84%, respectively. There were no mortalities within three years in the ER + AT group. The RFS between the two groups was also not significantly different (P = 0.938). The 1-, 2-, and 3-year RFS of patients in the esophagectomy group was 90%, 90%, and 83%, respectively, while it was 97%, 94%, and 74% in the ER + AT group, respectively. The local recurrence rates between the two groups were not significantly different (P = 0.277). CONCLUSIONS: This first multicenter analysis showed similar outcomes were found regarding OS and RFS between the two groups in T1aM3-T1b stage patients. ER + AT may be considered in high-risk patients or for those who refuse esophagectomy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00464-021-08466-2. |
format | Online Article Text |
id | pubmed-8979881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-89798812022-04-22 Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer Huang, Binhao Xu, Maria Christine Pennathur, Arjun Li, Zhigang Liu, Zhiguo Wu, Qi Wang, Jing Luo, Kongjia Bai, Jianying Wei, Zhi Xiang, Jiaqing Fang, Wentao Zhang, Jie Surg Endosc Article OBJECTIVE: To evaluate the outcome following the strategy of endoscopic R0 resection (ER) plus adjuvant treatment (AT) versus esophagectomy for esophageal squamous cell cancer in T1a invading muscularis mucosa (M3)-T1b stage. METHODS: We evaluated the outcomes of 46 esophageal squamous cell cancer (ESCC) patients with T1aM3-T1b stage who underwent ER + AT from the Esophageal Cancer Endoscopic Therapy Consortium (ECETC) and compared these outcomes to 92 patients who underwent esophagectomy. Propensity score matching (1:2) was used, with overall survival (OS) and relapse-free survival (RFS) being compared between the two groups. RESULTS: During a median follow-up of 32 months, there were no statistical differences (P = 0.226) in OS between the two groups. The 1-, 2-, and 3-year overall survival in the esophagectomy group was 95%, 91%, and 84%, respectively. There were no mortalities within three years in the ER + AT group. The RFS between the two groups was also not significantly different (P = 0.938). The 1-, 2-, and 3-year RFS of patients in the esophagectomy group was 90%, 90%, and 83%, respectively, while it was 97%, 94%, and 74% in the ER + AT group, respectively. The local recurrence rates between the two groups were not significantly different (P = 0.277). CONCLUSIONS: This first multicenter analysis showed similar outcomes were found regarding OS and RFS between the two groups in T1aM3-T1b stage patients. ER + AT may be considered in high-risk patients or for those who refuse esophagectomy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00464-021-08466-2. Springer US 2021-04-23 2022 /pmc/articles/PMC8979881/ /pubmed/33893544 http://dx.doi.org/10.1007/s00464-021-08466-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Huang, Binhao Xu, Maria Christine Pennathur, Arjun Li, Zhigang Liu, Zhiguo Wu, Qi Wang, Jing Luo, Kongjia Bai, Jianying Wei, Zhi Xiang, Jiaqing Fang, Wentao Zhang, Jie Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer |
title | Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer |
title_full | Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer |
title_fullStr | Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer |
title_full_unstemmed | Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer |
title_short | Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer |
title_sort | endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979881/ https://www.ncbi.nlm.nih.gov/pubmed/33893544 http://dx.doi.org/10.1007/s00464-021-08466-2 |
work_keys_str_mv | AT huangbinhao endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer AT xumariachristine endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer AT pennathurarjun endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer AT lizhigang endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer AT liuzhiguo endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer AT wuqi endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer AT wangjing endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer AT luokongjia endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer AT baijianying endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer AT weizhi endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer AT xiangjiaqing endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer AT fangwentao endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer AT zhangjie endoscopicresectionwithadjuvanttreatmentversusesophagectomyforearlystageesophagealcancer |